Overview

Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Status:
Withdrawn
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.
Phase:
Phase 1
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.